Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Exelixis Inc (NASDAQ: EXEL) closed at $38.91 down -2.26% from its previous closing price of $39.81. In other words, the price has decreased by -$2.26 from its previous closing price. On the day, 2.01 million shares were traded. EXEL stock price reached its highest trading level at $39.99 during the session, while it also had its lowest trading level at $38.56.
Ratios:
For a deeper understanding of Exelixis Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.89. For the most recent quarter (mrq), Quick Ratio is recorded 3.44 and its Current Ratio is at 3.51. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
On September 17, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $47.Goldman initiated its Buy rating on September 17, 2025, with a $47 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 02 ’25 when Eckhardt Sue Gail sold 18,838 shares for $42.74 per share. The transaction valued at 805,140 led to the insider holds 21,380 shares of the business.
WYSZOMIERSKI JACK L sold 7,535 shares of EXEL for $324,683 on Jun 03 ’25. The Director now owns 358,882 shares after completing the transaction at $43.09 per share. On Jun 03 ’25, another insider, JACK L WYSZOMIERSKI, who serves as the Director of the company, bought 7,535 shares for $43.09 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXEL now has a Market Capitalization of 10474670080 and an Enterprise Value of 9863413760. As of this moment, Exelixis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.66, and their Forward P/E ratio for the next fiscal year is 12.42. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.59. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.70 while its Price-to-Book (P/B) ratio in mrq is 5.17. Its current Enterprise Value per Revenue stands at 4.423 whereas that against EBITDA is 12.621.
Stock Price History:
The Beta on a monthly basis for EXEL is 0.37, which has changed by 0.48285055 over the last 52 weeks, in comparison to a change of 0.15535986 over the same period for the S&P500. Over the past 52 weeks, EXEL has reached a high of $49.62, while it has fallen to a 52-week low of $25.17. The 50-Day Moving Average of the stock is -1.11%, while the 200-Day Moving Average is calculated to be 1.72%.
Shares Statistics:
For the past three months, EXEL has traded an average of 3.14M shares per day and 2785160 over the past ten days. A total of 270.13M shares are outstanding, with a floating share count of 260.65M. Insiders hold about 3.18% of the company’s shares, while institutions hold 95.78% stake in the company. Shares short for EXEL as of 1756425600 were 17632257 with a Short Ratio of 5.62, compared to 1753920000 on 17367631. Therefore, it implies a Short% of Shares Outstanding of 17632257 and a Short% of Float of 9.0299994.
Earnings Estimates
The stock of Exelixis Inc (EXEL) is currently in the spotlight, with 12.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.65, with high estimates of $0.7 and low estimates of $0.6.
Analysts are recommending an EPS of between $2.79 and $2.64 for the fiscal current year, implying an average EPS of $2.71. EPS for the following year is $3.11, with 12.0 analysts recommending between $4.05 and $2.35.
Revenue Estimates
A total of 17 analysts believe the company’s revenue will be $589.43M this quarter.It ranges from a high estimate of $633M to a low estimate of $571.52M. As of. The current estimate, Exelixis Inc’s year-ago sales were $539.54MFor the next quarter, 17 analysts are estimating revenue of $606.66M. There is a high estimate of $649M for the next quarter, whereas the lowest estimate is $523.84M.
A total of 19 analysts have provided revenue estimates for EXEL’s current fiscal year. The highest revenue estimate was $2.4B, while the lowest revenue estimate was $2.22B, resulting in an average revenue estimate of $2.32B. In the same quarter a year ago, actual revenue was $2.17BBased on 19 analysts’ estimates, the company’s revenue will be $2.61B in the next fiscal year. The high estimate is $2.97B and the low estimate is $2.33B.
